Zacks Investment Research on MSN
NVO rallies 11% in a month: How should investors play the stock?
Novo Nordisk NVO shares have rallied 11.2% over a month as investors regained confidence in the company's obesity growth ...
Zacks Investment Research on MSN
LLY hits another record high: Is the stock too expensive to buy now?
Eli Lilly LLY shares climbed to another all-time high of $1,235.56, pushing the drugmaker's market capitalization to roughly ...
Kailera Therapeutics' oral obesity drug helped patients lose up to 10.9% of their body weight at week 44 in a late-stage ...
Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 8 Hidden Multibagger Stocks to Buy Now. On June 7, Cantor Fitzgerald ...
Nxera Pharma, which has Cambridge, London and Tokyo facilities, is cashing in big time on a highly profitable collaboration ...
Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.
Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 10 best mid-cap stocks that could double your money. On June 11, H.C. Wainwright reduced its price target on Structure Therapeutics Inc. (NASDAQ ...
XtalPi has entered a strategic partnership with a biopharmaceutical company to develop oral small-molecule therapeutics targeting a GPCR.
Tokyo, Japan and Cambridge, UK, 10 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)　announces that it has joined OpenFold, a ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...
Publication presented concurrently with oral presentation at American Diabetes Association’s 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results